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How common is early CKD?
Reduced eGFR—does this mean CKD?
Laura E. Clark1, Gordon Prescott1, Nicholas Fluck2, William Simpson2, W. Cairns. S. Smith1
and Alison M. Macleod1
1University of Aberdeen and 2NHS Grampian
Chronic kidney disease (CKD) is a growing public health
concern. We aimed to establish with increased accuracy
the prevalence of CKD in those with at least 1 creatinine
150mmol/l (males) and 130mmol/l (females) in a
6-month period in Grampian (population 500 000).
In a linked study (Poster Dr TZ Ali), 1918 patients
could not be classified as having CKD as they
did not fulfil our original criteria. 1405 of these have
been analysed to date. All available creatinines were
converted to eGFR (abbreviated MDRD formula)
and patients were grouped according to their
likelihood of having CKD. Unlikely n¼ 80 (5%),
Possible n¼ 245 (17%), Probable n¼ 933 (66%) and
insufficient data n¼ 147(10%).
Those in the ‘Probable’ group were staged according
to their index eGFR. Markers of kidney damage
determined from case note review allowed a further 61
patients to be staged (994 in total). Of these, 82%
are in Stage 3, 17.7% Stage 4 and 0.3% in Stage 5.
Hypertension and ischaemic heart disease were the
most common comorbidities. Mortality in Stage 3 was
45% at 30–36 months.
131 patients in the ‘Unlikely’ group without
markers were classed as having no definite
evidence of CKD (5% of 1405). The remaining 336
patients had insufficient data for classification
(25% of 1405).
70% (994) of patients in this study have evidence
of CKD. A substantial minority (30%) have no
conclusive evidence of CKD. These patients may
have been included in other prevalence studies
thus overestimating the prevalence of CKD.
Epidemiology of chronic kidney disease—a population-based study
T. Z. Ali1, A. M. MacLeod1, J. Townend1, W. C. Smith1, W. Simpson2 and I. H. Khan2
1University of Aberdeen and 2NHS Grampian
Chronic kidney disease (CKD) is a major public
health problem. Most of the studies of prevalence are
based on a single measure of renal function. We
hypothesize that this may overestimate the prevalence
of CKD.
In Grampian, we identified all patients with index
serum creatinine concentrations 150 mmol/l (male) or
130 mmol/l (female) over a 6-month period between
1 January 2003 and 30 June 2003. CKD was defined as
three elevated creatinine values (going back as far as
1996) each separated by at least 1 month with the rise
sustained for 12 months. Patients were placed in
stages 3–5 (KDOQI) after estimating GFR (MDRD
equation). All case notes were studied.
25 275 elevated creatinines from 5321 patients
were identified. 2315 (44%) were defined as having
CKD. Eighty-three percent were 65 years old and
89% had two or more comorbid conditions: only 23%
were known to renal physicians, 18% had died
at 12 months. 324 patients were receiving RRT and
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88 patients had acute on chronic renal failure.
The prevalence of CKD in this 6-month period was
5454 pmp.
Of the remaining 2594, 474 had acute renal failure
(ARF) according to the ADQI criteria, 202 were visitors
to this area. 1918 (36%) were unclassified: many with
fluctuating levels of creatinine and it was unclear
whether these had CKD.
CKD prevalence may be overestimated by using single
elevated creatinine. Most patients are not known to
renal physicians although the new Quality and
Outcomes Framework (QOF) is changing this.
Prevalence of patients with chronic kidney disease attending
the South East Essex Heart Failure Service
Jan Minter1, Kathy Halliday1, Janet Gawthorp1, Paul Mackenzie2 and David Carmichael3
1South East Essex Heart Failure Service, 2Biochemistry Department and 3Renal Unit, Southend Hospital NHS Trust,
Prittlewell Chase, Westcliff on Sea, Essex, SS0 0RY
Background. Patients with chronic heart failure (CHF)
may have evidence of renal impairment, usually
ascribed to a combination of poor cardiac output
and the use of ACE-I, ARBs and diuretics.
We have audited the prevalence of renal impairment
in patients under the care of the South East
Essex Heart Failure Service (SEEHFS) during the
latter part of 2005 and for 3 months in 2006 intending
to develop pathways to manage chronic kidney
disease (CKD).
Methods. Any patient with a serum creatinine
>12 mmol/l during July–December 2005 had a retro-
spective eGFR (MDRD) calculated. Patients known to
the renal service or with renal imaging were identified.
Patients in July–September 2006 in whom eGFR was
available were subject to a similar process with review
of urinalysis.
Results. In 2005, 481 patients were on the SEEHFS
register. 155 had a serum creatinine >12 mmol/l;
99 Men CKD: stage 3 89; stage 4 3 and stage 5 1
(on HD); 56 women: stage 3 33, Stage 4 6 and Stage
5 1. Of the 149 patients in Stages 3–5, 63 were known
to the renal service; and of these 34 had had no
imaging (18 normal and 11 abnormal). In 2006, there
were 700 patients. 193 had eGFR measured in
Aug–Sept. 143 men: stage 3 82, stage 4 13 and stage
5 1; 50 women: stage 3 26, stage 4 5 and stage 5 1. Of
the 20 in stage 4 or 5, 3 men and 1 woman were known
to the renal service; urinalysis was available in 8.
Conclusions. The prevalence of CKD 4 and 5 is lower
than we expected. We have recommended routine
urinalysis on presentation, informal discussion of cases
with a renal physician and use of CKD guidelines with
primary care.
Prevalence of CKD in high-risk patients in an urban general
practice—comparison of Cockcroft–Gault and MDRD formulae
Kirsteen Houston1, Brian Houston1 and David Carmichael2
1Highlands Surgery, 1643 London Road, Leigh on Sea, Essex, SS9 2UT and 2Renal Unit, Southend Hospital NHS Trust,
Westcliff on Sea, Essex SS0 0RY
Background.Guidelines for the management of chronic
kidney disease (CKD) based on eGFR (MDRD) were
introduced in South East Essex on 1 June 2006.
Reports suggest that eGFR may underestimate renal
function. We have, therefore, compared the prevalence
of CKD stage 3–5 by applying both Cockcroft–Gault
(C–G) calculated creatinine clearance (CrCl) and
eGFR to a high-risk group.
Methods. Patients with a diagnosis of ischaemic heart
disease, cerebrovascular disease, diabetes, hyperten-
sion, heart failure, renal disease or cardiomyopathy
were identified. Patients with an eGFR in the study
period had a CrCl calculated. BMIs were recorded.
Results. A total of 1776 patients out of a practice
population of 10 472 were considered high risk.
523 had results available. MDRD eGFR >60ml/min
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368 patients; Stage 3 147; Stage 4 11; Stage 5 1. C–G
CrCl >60ml/min 266; Stage 3 242; Stage 4 17;
Stage 5 1. Of the 122 patients reclassified from CrCl
in stage 3 to eGFR >60ml/min, 54 had a body mass
index <24, 43 BMI 25–29, 5 BMI 30þ.
Conclusions. These results suggest that MDRD
does not underestimate renal function if compared
with C–G. There has been less reclassification in
CKD stage 3 than expected. Low CrCl may be a
reflection of BMI.
The impact of a cooked meat meal on creatinine, eGFR
and the staging of chronic kidney disease
David Preiss1, Ian Godber1, Edmund Lamb2, Neil Dalton3 and Ian Gunn1
1Wishaw General Hospital, 2Kent and Canterbury Hospital and 3Guy’s Hospital, London
Background. Recent national guidelines have
recommended that biochemistry laboratories report
estimated GFR (eGFR) to improve the diagnosis,
staging and management of chronic kidney disease
(CKD). The guidelines do not mention the possible
effect of diet on serum creatinine concentration.
Previous reports have suggested that intake of
large amounts of cooked meat leads to a significant
increase in serum creatinine concentration.
Methods. Measurement of serum creatinine (kinetic
Jaffe method, enzymatic, IDMS) and cystatin-C,
calculation of eGFR, and staging of CKD was carried
out on 32 participants before and after a meal contain-
ing cooked meat and a meat-free meal. Post-prandial
samples were taken after 1–2 and 3–4 h. Meat-
containing meals included lamb, beef and chicken.
Results. Following intake of cooked meat,
median serum creatinine concentration (kinetic
Jaffe) increased from 80.5 mmol/l pre-prandially to
101.0mmol/l 1–2 h post-prandially (P< 0.0001) and
99.0mmol/l 3–4 h post-prandially (P< 0.0001).
Median eGFR decreased from 84.0ml/min/1.73m2
pre-prandially to 59.5ml/min/1.73m2 1–2 h post-
prandially (P< 0.0001) and 64.0ml/min/1.73m2 3–4 h
post-prandially (P< 0.0001). Consumption of non-
meat-containing meals had little impact on serum
creatinine concentration (kinetic Jaffe) and eGFR
CKD staging deteriorated in 12 cases after eating
cooked meat. It changed from better than CKD3 to
CKD3 in 11 individuals and from CKD3 to CKD4 in
one individual. Cystatin-C concentrations were unaf-
fected by either meal.
Conclusions. Intake of cooked meat has a significant
impact on serum creatinine concentration and eGFR,
making misclassification of CKD likely. CKD staging
must be based on samples taken in the appropriate
conditions. National guidelines overlooking this factor
should be revisited.
Is early CKD an important risk factor for cardiovascular disease?
Chronic kidney disease stage is a prognostic indicator in stroke
patients both in the short-term and in the long-term
Louise F. Porter and Ronald S. MacWalter
Stroke Studies Centre, Division Of Medicine And Therapeutics, Ninewells Hospital And Medical School, Dundee,
DD1 9SY, Scotland, UK
Background. Renal dysfunction is an important,
often forgotten prognostic indicator in acute
stroke. The objective of this study was to
investigate whether chronic kidney disease
(CKD) stage using the 4-variable Modified Diet in
Renal Disease (4-v MDRD) study equation can
predict short- and/or long-term survival after
acute stroke.
Methods. Cohort study in a Scottish tertiary teaching
hospital. Participants included 2042 unselected
ix56 Poster Abstracts
consecutive stroke patients admitted to hospital within
48 h of stroke between 1988 and 1994. Main outcome
measure was long-term survival (up to 7 years of
follow-up) and short-term survival (30-day survival).
Estimated glomerular filtration rate (eGFR), calcu-
lated using the 4-v MDRD study equation, was
correlated with that calculated with the Cockcroft–
Gault formula. We analysed eGFR to categorize into
CKD stages and estimated relative risks of mortality
(RR) with 95% confidence intervals (CI) using Cox
proportional-hazard models.
Results. 1026 patients died during the follow-up
period. The eGFR calculated with the 4-v MDRD
formula correlated significantly with that using the
Cockcroft–Gault formula (Pearson 0.897,
two-tailed P< 0.0001). CKD stage predicted survival
to 30 days (log-rank test P< 0.00001) and overall
survival (log- test P< 0.00001).
Conclusions. CKD stage at time of stroke predicts
survival in the short-term (30 days) and in the long-
term (to 7 years). CKD stages 4 and 5 with estimated
GFR under 30ml/min were associated with the poorest
outcomes. The 4-v MDRD formula for eGFR and
CKD stage assessment may be used to risk-stratify
stroke patients on admission and target further
treatments.
How does early CKD progress?
Managing nephrology outpatients—too many inappropriate referrals?
Not enough nephrologists
M. Quinn1, A. Rainey2, K. J. Cairns2, A. H. Marshall2, F. Kee1, G. Savage1 and D. G. Fogarty3
1Department of Public Health and Epidemiology, 2Centre for Statistical Science and Operational Research (CenSSOR),
and 3Department of Nephrology, The Queen’s University of Belfast
Background. Chronic kidney disease (CKD) is now
recognized as a common condition and is associated
with end-stage renal failure (ESRF) and premature
cardiovascular death. The Renal Association have
published referral guidelines for CKD re-emphasizing
the importance of assessing patients with progressive
CKD at Nephrology outpatients.
Methods. 2 892 340 routine blood samples collected
in Northern Ireland between 1 January 2001 and
31 December 2002 were compared with an enriched
Data Retrieval in General Practice (DRGP) data set
and thereafter, applying the MDRD eGFR equation, a
patient-level database of 75 434 with 307 663 results
was produced. A three-point assessment of progression
over the entire period was devised. Patients were then
categorized depending on their change in eGFR in
relation to the threshold of 60ml/min. eGFR slopes
were categorized as stable, slow and rapid.
Results. 61 373 (81.4%) subjects had an eGFR>60 and
14 061 (18.6%) had an eGFR<60 at the end of
the study. In total, 1167 were known to Nephrology.
Of these, 29.2% had an eGFR>60 over the 2 year
period. Importantly 2699 (3.6%) subjects unknown
to nephrology demonstrated a rapid decline from
stage 1 or 2 CKD to stage 3 CKD.
Conclusion. Significant numbers of subjects
attending nephrology services have no evidence of
progressive decline in eGFR whilst the vast majority
with CKD remain unseen. Although some of these
patients may have important reasons for attending
Nephrology services, this may be to the detriment of
those with more progressive CKD.
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eGFR—an intuitive method of assessing progression and regression
of chronic kidney disease (CKD)
A. Rainey1, M. Quinn2, K. J. Cairns1, A. H. Marshall1, F. Kee2, G. Savage1 and D. G. Fogarty3
1Centre for Statistical Science and Operational Research (CenSSOR), 2Department of Public Health and Epidemiology,
and 3Department of Nephrology, The Queen’s University of Belfast
Background. The number of patients receiving renal
replacement therapy in the UK is rising rapidly,
costing over 2% of the total NHS budget. The Renal
Association’s CKD guidelines emphasize the
importance of assessing patients with progressive
disease based on eGFR.
Methods. In Northern Ireland, 2 892 340 creatinine
samples from 1 January 2001 to 31 December 2002
were extracted from regional laboratories. Merging
these to an enriched General Practice data set
produced a cohort of 75 434 subjects containing
307 663 results. To capture progression over the
2-year period, a three-point assessment was devised.
Progression and periods of regression were character-
ized by the gradients A and B. A cut-off level
(eGFR 60ml/min) was additionally used to categorize
the change in patient’s eGFR. Progression was also
categorized as stable, slow and rapid.
Results. 56 356 (74.7%) subjects had ‘all eGFR results’
>60 throughout the entire period. 14 061 (18.6%) had
an eGFR<60 at the end of the study. 5017 (6.7%)
subjects had a minimum eGFR measured <60ml/min,
and yet subsequently had a value >60ml/min.
Improvements in kidney function are common and in
some patients are part of the natural history of CKD.
Conclusion. Progression of CKD is often taught to be
linear; this data indicates that alternative patterns of
progression occur in the natural history of CKD,
including improvement in function. This suggests,
although further study is needed, that repeated
sampling and the use of simple gradient functions are
critical in monitoring CKD.
Can patients with stage 4 CKD be safely discharged to primary care?
B. Conway1,3, G. Ramsay2, A. Webster1, J. Neary1, C. Whitworth1 and J. Harty3
1Department of Nephrology, Royal Infirmary Edinburgh, 2University of Edinburgh and 3Renal Unit, Daisy Hill Hospital,
N. Ireland
Background. Current guidelines recommend that all
patients with stage 4 CKD be discussed with a
nephrologist, however, as stage 4 CKD affects
0.5% of the population, it would be impractical for
nephrologists to manage all such patients. Many
patients will be elderly with stable renal function;
therefore, we sought to determine whether this
subgroup could be safely discharged to primary care.
Methods. This was a retrospective, two-centre study
that enrolled all patients with stage 4 CKD who
were referred to the nephrology services of the
Southern Health Board in Northern Ireland and
the Lothian and Borders regions of Scotland between
1998 and 2002 inclusive. Patients were followed until
end 2005 to determine factors conferring risk of
renal replacement therapy (RRT) or death.
Results. We identified 424 patients with stage 4 CKD.
After 5 years follow-up, 27.4% progressed
to RRT, 49.7% died, while 34.4% remained alive
without RRT. The risk of RRT increased with:
younger age, male sex, higher baseline proteinuria
and diastolic BP, lower baseline haemoglobin and
eGFR and a more rapid early rate of deterioration
in eGFR. During follow-up, 96 (23%) patients
were discharged to primary care, five of whom
were subsequently re-referred; however, none required
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RRT. The median rate of change in renal function
was þ0.41ml/min/m2/year in patients following dis-
charge, and 2.04ml/min/m2/year in those continuing
in nephrological follow-up (P< 0.0001)
Conclusion. Baseline clinical parameters and
historic rate of decline in renal function can be used
to identify a group of patients with stage 4 CKD who
can be safely discharged to primary care.
What are the best treatments for early CKD?
Slowing the progression of CVD and CKD—an audit of a DGH
nephrology clinic
Walaa W. M. Saweirs and Paddy H. Gibson
Department of Renal Medicine, Royal Infirmary of Edinburgh, Little France, Old Dalkeith Road, Edinburgh, EH16 4SU
Background. The two principle outcomes of chronic
kidney disease (CKD) are the progressive loss of renal
function, and the development and progression of
cardiovascular disease (CVD). We undertook an audit
of modifiable risk factors for both CKD and CVD
progression in a district hospital nephrology clinic.
Findings. The average age of attending patients was
59.4 years, with 59% being male. Approximately 30%
of patients attending the clinic were at each of CKD
stages 3 and 4. Fifty-five percent were non-smokers.
Twenty-eight percent had documented ischaemic heart
disease. Diabetes was the cause of renal impairment in
21%, with glomerulonephritis forming 13% and
renovascular disease 10% of cases. A target blood
pressure was set in an average of 60% of cases, with
this being attained in under 50%. Proteinuria was
quantified in about 40% of cases and renin–angioten-
sin blockers were used in a similar proportion. The
HbA1c target was achieved in less than one-third of
diabetic patients. Cholesterol targets were achieved
in less than 15% of patients, with only 40% being
prescribed a ‘statin’.
Discussion.With the establishment of eGFR reporting,
the expansion of the GP GMS contract into CKD and
the development of CKD guidelines, it is important
that nephrologists take this opportunity to reduce the
burden not only of CKD progression but its attended
burden of CVD. We have designed a management
algorithm for CVD risk factors based around the
current JBS2 guidelines. The plan is to close the audit
loop at the beginning of 2007.
How do we re-design the treatment?
Supporting early chronic kidney disease (CKD) management
in primary care—Walsall/Wolverhampton Collaboration
P. Giles1, A. Hartland1, P. Rylance2, J. Nicholas2, H. Ashby1, A. Askey3, D. Crothers1
and B. Patel4
1Department of Biochemistry, Walsall Manor Hospital, 2Wolverhampton Renal Unit, 3Walsall GP and 4Locality Lead
Pharmacist
Wolverhampton nephrologists provide weekly clinics
in Walsall, supported by Walsall chemical
pathologists. Referrals are often unsatisfactory:
advanced nephropathy may present late; patients
with microalbuminuria but no other sign of renal
disease are sometimes referred unnecessarily.
After widespread consultation two flow-charts, based
on national guidelines, were formulated to
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help primary care with the renal management of
diabetic and hypertensive patients. The assumption
was that much primary care CKD management
could be incorporated within their established
mechanisms for the review of these underlying
chronic conditions.
The charts were distributed electronically in
November 2005. However, a subsequent survey
showed that many GPs were unaware of these
materials so a new approach was tried. Walsall
conducts outreach education campaigns to primary
care on prescribing issues. This vehicle was
exploited to distribute hard-copy of the flow-charts
during individual practice visits by trained
pharmacists, often accompanied by a chemical
pathologist. MDRD eGFR, CKD registers and the
flow-charts (which include aspects of treatment) were
covered.
Audit of 500 diabetics aged 18–70 years assessed
potential demand for nephrological advice arising from
flow-chart recommendations. About 5% of patients on
the basis of creatinine/eGFR results and/or significant
urinary abnormalities warranted expert advice, albeit
not necessarily clinic referral. Of these, only a third had
been referred. Extrapolating to the entire local
population, clinic capacity would be overwhelmed
were all these patients referred. Minimal inappropriate
referrals occurred in this cohort.
Optimizing CKD management outside conventional
renal clinics, mainly in primary care, is essential;
clinical biochemistry and practice pharmacists can
help.
Efficient and educational—a consultant-provided renal e-mail helpline
for primary care
John Main1 and Dinah Roy2,3
1James Cook University Hospital, Middlesbrough, 2PEC Chair and 3GP, Sedgefield PCT
A hospital-based e-mail helpline was set up in June
2006 to help GPs deal with the introduction of
CKD guidelines and eGFR measurements. The
Middlesbrough renal unit serves a catchment
population of 1 million, but the e-mail helpline was
initially advertised only to practices serving less than
half of that area.
By late October, there had been 43 e-mails to the
helpline, 30 in the most recent 8 weeks. These
contained 36 enquiries about specific patients and
10 general questions. Only one enquiry was inap-
propriate (paediatric) although three were largely
urological. For the specific enquiries, patient age
range was 14–98, median 77. The commonest reasons
for enquiry were stable stage 4 chronic kidney disease
(n¼ 12), followed by recent worsening of already
impaired renal function (n¼ 6). Twenty-eight related
to CKD. In only two cases was referral to renal OP
clinic deemed necessary.
Six of the 10 general enquiries related to CKD and/
or eGFR.
Twenty-nine replies were on the same day as
receipt of the enquiry and 34 within 1 day. All replies
were by consultant nephrologists, who aimed not only
to give specific advice but also to explain the reasoning
behind their decisions. Forty of the 46 enquiries could
be dealt with in a single reply. One enquiry eventually
involved two nephrologists and four GPs. Unsolicited
compliments and thanks were received on eight
occasions.
The introduction of CKD guidelines and eGFR
measurement identifies high levels of CKD, especially
in elderly patients with multiple comorbidities.
An e-mail helpline allows GPs virtually instant access
to consultant nephrologists to discuss these patients.
Medical management of their CKD can be
optimized whilst avoiding unnecessary hospital visits
for patients, the majority of whom are over 75.
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Managing CKD in the community—a successful model
Indranil Dasgupta and Hugh Rayner
Heart of England Foundation Trust, Birmingham
Since the inclusion of chronic kidney disease (CKD)
into the Quality and Outcomes Framework (QOF)
there has been significant increase in the number of
patients being treated in general practice and the
number referred to hospitals. Early identification of
CKD in primary care is essential to manage the high
risk of cardiovascular morbidity and mortality in these
patients, to slow progression to end-stage kidney
disease and to identify patients who will need dialysis
at an early stage.
At the Heart of England Foundation Trust, we have
been automatically reporting estimated eGFR since
January 2004. GFR estimates are only reported when
the serum creatinine concentration is above the
laboratory assay’s reference range (80mm/l for
women, 106 mm/l for men). We contend that estimates
of GFR derived from creatinine values in the reference
range do not add clinically useful information to the
result and often cause unnecessary anxiety. We
developed a simple flow chart for the management
of patients with CKD (http://www.heartofengland.nhs.
uk/resources/clinical/docs/GFR_GP_algorithm.pdf).
We have also run a series of CKD education sessions
for GPs and practice nurses.
In the first year, referrals increased by 25% but the
additional numbers of patients could be treated
and monitored in primary care, as per the flow chart.
Letters of advice specific for each patient were sent
to the referring GP rather than a routine outpatient
appointment being offered. We have also set up
systems to help manage CKD in the community,
including regular training sessions for practice nurses
and the establishment of a community CKD nurse.
With a rational eGFR reporting system, a thorough
education programme and true partnership between
primary and secondary care, our local GPs have
become more confident in managing CKD, the out-
patient service is controlled and an improved service
is being provided for patients.
Primary care-based disease management (DMP) improves outcomes
and reduces resource utilization in patients with CKD
N. T. Richards1, M. Eames2, R. Lewis3, M. Mansell4, J. Townend5, S. Thomas6, D. O’Donoghue7
and K. Harris8
1Optimal Renal Care UK, Birmingham, 2Department of Surgery, WLPCT, Market Rasen, 3Department of Nephrology,
Queen Alexandra Hospital, Portsmouth, 4Department of Nephrology, Royal Free Hospital, London, 5Department of
Cardiology, University Hospital, Birmingham, 6Department of Diabetology, Guys and St Thomas Hospital, London,
7Department of Nephrology, Hope Hospital, Salford and 8Department of Nephrology, ULH, Leicester, UK
Background. The prevalence of CKD 3–5 in the UK is
5%. There is evidence of historic under-diagnosis and
referral.
Methods. A primary care-based disease management
(DMP) for CKD commenced in West Lincolnshire
UK in 2005 aiming to improve patient identification
and outcomes. The programme relies on automated
patient identification via eGFR (MDRD). Patients
are risk-stratified and managed by a community-based
nursing team to defined and audited outcome targets.
Results. In the first 18 months 16 500 patients with
CKD 3–5 were identified suggesting a prevalence
of 8.4%. 989 patients had CKD 4/5 compared with
38 patients with CKD4/5 who had been referred to
nephrology in the previous year. Around 84, 85, 57
and 20% of patients with CKD 2–5 respectively were
identified in primary care (PC). Only 0.3, 2, 29
and 70%, respectively were identified from
nephrology care; the remainder were followed up in
non-nephrology secondary care. The latter were more
likely to have a previous and future nephrology referral
than those identified from PC (P< 0.001). In 2004/
2005, 53 patients with CKD 4/5 presented toCorrespondence to: N. T. Richards.
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nephrology. Eleven (20.8%) died within 12 months. Of
the 989 patients identified in 2005/2006, 483 were
enrolled in the DMP, 50 died (10.4%, P< 0.05).
In 2004/2005, 38% of patients commenced dialysis
with <3 months pre-dialysis care compared with 26%
in 2005/2006.
Seventy-four patients had a decline in eGFR of
>5ml/min in the 9 months prior to joining the DMP.
In 23 patients, the rate of decline reduced and in
20 patients renal function improved after joining
the DMP. When compared with a cohort of
patients with similar renal function the DMP patients
experienced less A&E attendances, less inpatient
stays, less days in hospital and less outpatient visits
(24 vs 81; 25 vs 69; 227 vs 526/100 patient-years, and
3.3 vs 82/patient-years, respectively). The reduction in
resource utilization and delay in start of dialysis
correspond to a saving of in excess of £1 million
per year.
Conclusion. These data confirm prior under diagnosis
and referral and demonstrate that this DMP improves
patient identification and outcomes against clinical
targets whilst reducing resource utilization.
Table 1 shows the percentage of patients achieving the
defined biochemical targets.
Table 1. Percentage of patients achieving specified target
6 months prior
to DMP
At entry
to DMP
9 months
of DMP
Entry vs
9 months
Total cholesterol
<5mmol/l
67.3 64.4 75.0 P< 0.001
LDL cholesterol
<3mmol/l
72.3 69.1 81.9 P< 0.05
Triglycerides
<2mmol/l
65.3 64.9 70.9 P< 0.05
Systolic BP
<130mmHg
37.1 46.2 53.2 P< 0.05
Diastolic BP
<80mmHg
68.3 70.0 90.0 P< 0.01
Ferritin
>150 g/l
79.5 49.5 68.1 P< 0.01
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